Characterization of Inhaled Nitric Oxide (iNO) for the treatment of Viral Community Acquired Pneumonia (CAP) Wolak T¹, Grossman A², Shifer Y², Dicker D², Tal A³

¹Shaare Zedek Medicl Center – Jerusalem, Israel. ²Rabin Medical Center – Petah Tikva, Israel. ³Beyond Air, LTD – Rehovot, Israel.

Background

COVID-19 infections are over 600 million cases and over 6.5 million deaths worldwide, as of September 2022

Continuously emerging COVID-19 variants pose a serious challenge for immunization strategies. This highlights the need for innovative treatment solutions.

Inhaled Nitric Oxide (iNO) has proven antimicrobial, anti-inflammatory, and vasodilator properties

➢ Previous iNO therapy at 150-250 ppm for various Lower Respiratory Tract Infections (LRTI) was shown to be well tolerated and safe and demonstrated positive efficacy trends.

Methods

Study Design:

Randomized, open label, multi-center pilot study

Evaluate the safety and efficacy of iNO for the treatment of hospitalized adults with COVID-19 or other viral LRTI

Treatment group:

iNO at 150 ppm delivered with the LungFit[™] PRO device, 40 minutes, 4 times daily for up to 7 days

Control group:

Standard Supportive Treatment (SST) Enrolled patients are followed for up to 180-day follow-up period

Study endpoints include safety and time on oxygen supplementation, among others

Study Device:


➢iNO was delivered by LungFit[™] PRO, an innovative portable device (Beyond Air[®], NY, USA) that generates NO from room air



Study Population

40 subjects hospitalized for viral pneumonia, incl. COVID-19 were randomized 1:1 to receive iNO at 150 ppm vs. SST. Intent To Treat (ITT) population included 35 subjects with 16 in the iNO group and 19 in the SST





Demographics		150 ppm NO + SST	SST	All
Number of patients	N (%)	16 (45.7)	19 (54.3)	35 (100)
Age (years)	Mean ,std	50.5, 16.1	53.2, 11.9	51.9, 13.8
Gender	Male, n (%)	9 (56.3)	17 (89.5)	26 (74.3)
	Female, n (%)	7 (43.8)	2 (10.5)	9 (25.7)
BMI (kg/m²)	Mean, std	28.8, 5.2	29.7, 2.5	29.3, 3.9
Viral infection	SARS-CoV2, n (%)	15 (93.8)	19 (100)	34 (97.1)
	Other, n (%)	1 (3.6)	0 (0)	1 (2.9)

Results

Demographics

Baseline Characteristics

Medical History		150 ppm NO + SST	SST
Chronic Medication, n (%)		10 (62.5)	11 (57.9)
Tobacco Use	No	12 (75.0)	17 (89.5)
n (%)	Former	2 (12.0)	1 (5.3)
	Current	2 (12.0)	1 (5.3)
Cardiac disorders, n (%)		2 (12.5)	2 (10.5)
Metabolic disorders, n (%)		7 (43.8)	9 (47.4)
Respiratory disorders, n (%)		2 (12.5)	4 (21.1)
Vascular disorders, n (%)		8 (50.0)	4 (21.1)

Disease-Related Baseline Characteristics		150 ppm NO + SST	SST
O2 required at baseline, n (%)	No	6 (37.5)	6 (31.6)
	Yes	10 (62.5)	13 (68.4)
COVID-	Remdesivir	7 (43.8)	6 (31.6)
related drugs, n (%)	Dexamethaso ne	11 (68.8)	14 (73.7)
	Baricitinib	1 (6.0)	1 (5.3)
	Dexacort forte	0 (0)	2 (10.5)

Safety


Adverse Events	150 ppm NO + SST		SST	
	n	%	n	%
Any AE	9	56.3	8	42.1
Any AE Classified as Moderate or Severe	4	25.0	3	15.8
Any AE Drug/Device- Related*	0	0	0	0
Any AE leading to early treatment termination**	2	12.5	1	5.3
Any SAE	2	12.5	0	0
Any SAE Drug/Device- Related*	0	0	0	0


*Including 'possibly related'


** AEs leading to early treatment termination: SST group - 1 subject suffered from hypoxemia *NO group-1 subject experienced bradycardia (pre-existing);* 1 subject experienced hypoxemia (unrelated to study treatment)

AE – Adverse Event; SAE – Serious Adverse Event

Pre treatment End treatment







1) iNO treatment delivered with LungFit PRO in patients with viral community-acquired pneumonia (97% COVID-19) was safe and well tolerated

control group with a significant reduction in the duration of oxygen support 3) A larger study in this patient population is warranted to confirm these results

2) There were indications of improved efficacy on multiple parameters in the iNO treatment group vs. the SST

